OnCo
peoplePerson

Rachel E. Rau

Paediatric oncologist who led the COG trial showing blinatumomab helps children with standard-risk leukaemia.

Pediatric hematologist-oncologist and study chair of COG AALL1731, which found adding blinatumomab to chemotherapy improved disease-free survival in newly diagnosed standard-risk B-ALL.

Role
Associate Professor of Pediatrics, Seattle Children's and University of Washington; Study Chair, COG AALL1731
Specialisms
Paediatric ALLImmunotherapyLeukaemia genomics

Papers

2top
TitleJournalYear
Blinatumomab in Standard-Risk B-Cell Acute Lymphoblastic Leukemia in ChildrenNew England Journal of Medicine2025
DOT1L as a therapeutic target for the treatment of DNMT3A-mutant acute myeloid leukemiaBlood2016

Key papers

1top
rctNew England Journal of Medicine 2025changed practice
Children's Oncology Group AALL1731: blinatumomab added to chemotherapy for children with standard-risk B-cell ALL

AALL1731 brings immunotherapy into the front-line treatment of the commonest childhood cancer, in the group of children where most relapses were occurring despite good initial risk. Blinatumomab was approved for this use in 2024 and paediatric protocols worldwide are being amended. Whether it can allow less chemotherapy, and its effect on very low-risk children, are the next questions.

Connected

6top

Pages like this

not linked directly; found by shared links

cancers

1
Acute lymphoblastic leukaemia

targets

1
CD19

drugs

1
ApprovedBispecific T-cell engager (CD19×CD3)
Blinatumomab · Blincyto

institutions

1
Children's Oncology Group (COG)

trials

1
COG AALL1731

key papers

1
Children's Oncology Group AALL1731: blinatumomab added to chemotherapy for children with standard-risk B-cell ALL